The Metabolic Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Metabolic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Metabolic Syndrome. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Metabolic Syndrome - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Metabolic Syndrome and features dormant and discontinued products.

GlobalData tracks 28 drugs in development for Metabolic Syndrome by 24 companies/universities/institutes. The top development phase for Metabolic Syndrome is preclinical with 18 drugs in that stage. The Metabolic Syndrome pipeline has 22 drugs in development by companies and six by universities/ institutes. Some of the companies in the Metabolic Syndrome pipeline products market are: Defensin Therapeutics, Renova Therapeutics and Yale University.

The key targets in the Metabolic Syndrome pipeline products market include Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF), Thromboxane A2 Receptor (Prostanoid TP Receptor or TBXA2R), and Soluble Guanylate Cyclase (sGC or EC 4.6.1.2).

The key mechanisms of action in the Metabolic Syndrome pipeline product include Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) Inhibitor with one drug in Preclinical. The Metabolic Syndrome pipeline products include four routes of administration with the top ROA being Oral and 11 key molecule types in the Metabolic Syndrome pipeline products market including Small Molecule, and Biologic.

Metabolic Syndrome overview

Metabolic syndrome, also known as insulin resistance syndrome, constitutes a cluster of conditions that collectively heighten the risk of coronary heart disease, diabetes, stroke, and other severe health issues. To be diagnosed with metabolic syndrome, one must exhibit three or more of the following conditions. A significant waistline, termed abdominal obesity or an “apple shape”, indicates a higher risk for heart disease than fat deposits in other body regions. Elevated blood pressure can lead to heart and vascular damage, contributing to plaque buildup in arteries. High blood sugar levels increase the risk of blood clots, potentially causing heart and vascular diseases. Elevated blood triglycerides and low HDL cholesterol levels further amplify the risk. In the US, approximately 1 in 3 adults contend with metabolic syndrome, but it is largely preventable through awareness of risk factors and adopting a healthy lifestyle.

For a complete picture of Metabolic Syndrome’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.